Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Eli Lilly posts blowout Q3 results, raises 2025 outlook, and sees strong demand for its GLP-1 medicines.
US and China agree to a one-year trade truce, pausing tariff threats and easing export controls, but core disputes remain unresolved.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Eli Lilly posts blowout Q3 results, raises 2025 outlook, and sees strong demand for its GLP-1 medicines.
US and China agree to a one-year trade truce, pausing tariff threats and easing export controls, but core disputes remain unresolved.